(Q43905985)

27 November 2017

title

Low-density lipoprotein apheresis: clinical results with different methods (English)

1 reference

27 November 2017

1 reference

Rolf Bambauer

1

1 reference

27 November 2017

language of work or name

1 reference

1 February 2002

1 reference

27 November 2017

1 reference

27 November 2017

volume

26

1 reference

27 November 2017

issue

2

1 reference

27 November 2017

page(s)

133-139

1 reference

Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study.

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1594.2002.06837.X

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1594.2002.06837.X

Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1594.2002.06837.X

The Helsinki Heart Study: central findings and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1594.2002.06837.X

Low serum total cholesterol concentrations and mortality in middle aged British men

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1594.2002.06837.X

Treating hypercholesterolemia. How should practicing physicians interpret the published data for patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1594.2002.06837.X

How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1594.2002.06837.X

Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1594.2002.06837.X

Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1594.2002.06837.X

Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1594.2002.06837.X

Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1594.2002.06837.X

Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1594.2002.06837.X

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1594.2002.06837.X

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1594.2002.06837.X

Portacaval shunt in four patients with homozygous hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1594.2002.06837.X

Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1594.2002.06837.X

Treatment of familial hypocholesterolemia by means of specific immunoadsorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1594.2002.06837.X

A new approach to the management of familial hypercholesterolaemia: Removal of plasma-cholesterol based on the principle of affinity chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1594.2002.06837.X

Using the WHO (Rose) angina questionnaire in cardiovascular epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1594.2002.06837.X

Effect of intensive plasmapheresis on the plasma cholesterol concentration with familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1594.2002.06837.X

Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. The Liposorber Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1594.2002.06837.X

The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concen

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1594.2002.06837.X

Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1594.2002.06837.X

Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1594.2002.06837.X

Lipoprotein(a) and Atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1594.2002.06837.X

The mysteries of lipoprotein(a)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1594.2002.06837.X

Lipoprotein (a). Heterogeneity and biological relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1594.2002.06837.X

Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1594.2002.06837.X

Design, rationale, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project—A combined analysis of three large-scale randomized trials: Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID), Cholesterol and Re

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1594.2002.06837.X

10.1046/J.1525-1594.2002.06837.X

21 January 2018

Identifiers

DOI

1 reference

27 November 2017

1 reference